300 related articles for article (PubMed ID: 37938756)
1. Lipoprotein(a), platelet function and cardiovascular disease.
Bhatia HS; Becker RC; Leibundgut G; Patel M; Lacaze P; Tonkin A; Narula J; Tsimikas S
Nat Rev Cardiol; 2024 May; 21(5):299-311. PubMed ID: 37938756
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.
Enas EA; Varkey B; Dharmarajan TS; Pare G; Bahl VK
Indian Heart J; 2019; 71(2):99-112. PubMed ID: 31280836
[TBL] [Abstract][Full Text] [Related]
3. Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic
Guertin J; Kaiser Y; Manikpurage H; Perrot N; Bourgeois R; Couture C; Wareham NJ; Bossé Y; Pibarot P; Stroes ESG; Mathieu P; Clavel MA; Thériault S; Boekholdt SM; Arsenault BJ
Circ Genom Precis Med; 2021 Aug; 14(4):e003271. PubMed ID: 34279996
[TBL] [Abstract][Full Text] [Related]
4. Aspirin and lipoprotein(a) in primary prevention.
Bhatia HS
Curr Opin Lipidol; 2023 Oct; 34(5):214-220. PubMed ID: 37527183
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study.
Naka KK; Bechlioullis A; Marini A; Sionis D; Vakalis K; Triantis G; Wilkins L; Rogus J; Kornman KS; Witztum JL; Doucette-Stamm L; Michalis LK; Tsimikas S
J Clin Lipidol; 2018; 12(2):338-347. PubMed ID: 29310992
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
Tsimikas S; Hall JL
J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties.
Rowland CM; Pullinger CR; Luke MM; Shiffman D; Green L; Movsesyan I; Devlin JJ; Malloy MJ; Kane JP; Undas A
Thromb Res; 2014 May; 133(5):863-7. PubMed ID: 24502962
[TBL] [Abstract][Full Text] [Related]
8. Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk.
Coassin S; Chemello K; Khantalin I; Forer L; Döttelmayer P; Schönherr S; Grüneis R; Chong-Hong-Fong C; Nativel B; Ramin-Mangata S; Gallo A; Roche M; Muelegger B; Gieger C; Peters A; Zschocke J; Marimoutou C; Meilhac O; Lamina C; Kronenberg F; Blanchard V; Lambert G
Circ Genom Precis Med; 2022 Apr; 15(2):e003489. PubMed ID: 35133173
[TBL] [Abstract][Full Text] [Related]
9. A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction.
Coassin S; Erhart G; Weissensteiner H; Eca Guimarães de Araújo M; Lamina C; Schönherr S; Forer L; Haun M; Losso JL; Köttgen A; Schmidt K; Utermann G; Peters A; Gieger C; Strauch K; Finkenstedt A; Bale R; Zoller H; Paulweber B; Eckardt KU; Hüttenhofer A; Huber LA; Kronenberg F
Eur Heart J; 2017 Jun; 38(23):1823-1831. PubMed ID: 28444229
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a).
Scipione CA; McAiney JT; Simard DJ; Bazzi ZA; Gemin M; Romagnuolo R; Macrae FL; Ariëns RA; Hegele RA; Auld J; Gauld JW; Boffa MB; Koschinsky ML
J Thromb Haemost; 2017 Sep; 15(9):1834-1844. PubMed ID: 28632940
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a): from Causality to Treatment.
Kronenberg F
Curr Atheroscler Rep; 2024 Mar; 26(3):75-82. PubMed ID: 38252372
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies.
Cesaro A; Schiavo A; Moscarella E; Coletta S; Conte M; Gragnano F; Fimiani F; Monda E; Caiazza M; Limongelli G; D'Erasmo L; Riccio C; Arca M; Calabrò P
J Cardiovasc Med (Hagerstown); 2021 Mar; 22(3):151-161. PubMed ID: 32858625
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a).
Kronenberg F
Handb Exp Pharmacol; 2022; 270():201-232. PubMed ID: 34196811
[TBL] [Abstract][Full Text] [Related]
14. How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?
Cui K; Yin D; Zhu C; Song W; Wang H; Jia L; Zhang R; Wang H; Cai Z; Feng L; Dou K
J Am Heart Assoc; 2022 May; 11(9):e023578. PubMed ID: 35475627
[TBL] [Abstract][Full Text] [Related]
15. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study.
Perrot N; Verbeek R; Sandhu M; Boekholdt SM; Hovingh GK; Wareham NJ; Khaw KT; Arsenault BJ
Atherosclerosis; 2017 Jan; 256():47-52. PubMed ID: 27998826
[TBL] [Abstract][Full Text] [Related]
16. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
Burgess S; Ference BA; Staley JR; Freitag DF; Mason AM; Nielsen SF; Willeit P; Young R; Surendran P; Karthikeyan S; Bolton TR; Peters JE; Kamstrup PR; Tybjærg-Hansen A; Benn M; Langsted A; Schnohr P; Vedel-Krogh S; Kobylecki CJ; Ford I; Packard C; Trompet S; Jukema JW; Sattar N; Di Angelantonio E; Saleheen D; Howson JMM; Nordestgaard BG; Butterworth AS; Danesh J;
JAMA Cardiol; 2018 Jul; 3(7):619-627. PubMed ID: 29926099
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
18. Targeting lipoprotein (a): an evolving therapeutic landscape.
Man LC; Kelly E; Duffy D
Curr Atheroscler Rep; 2015 May; 17(5):502. PubMed ID: 25736345
[TBL] [Abstract][Full Text] [Related]
19. Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases.
Kronenberg F
Cardiovasc Drugs Ther; 2016 Feb; 30(1):87-100. PubMed ID: 26896185
[TBL] [Abstract][Full Text] [Related]
20. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics.
Swerdlow DI; Rider DA; Yavari A; Wikström Lindholm M; Campion GV; Nissen SE
Cardiovasc Res; 2022 Mar; 118(5):1218-1231. PubMed ID: 33769464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
